康龙化成（北京）新药技术股份有限公司 2025 年半年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2025 年半年度报告 公告编号：2025-048 2025 年 08 月 1 康龙化成（北京）新药技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人 （会计主管人员）李承宗声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本次半年报的董事会会议。 报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，投资者及相关人士均应对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和应对 措施 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年8月21日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-041 康龙化成（北京）新药技术股份有限公司 第 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2025年6月30日止六個月中期業績公告 財務摘要及要點 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 人民幣千元 | 人民幣千元 | % | | 收益 | 6,440,951 | 5,604,463 | 14.9 | | 毛利 | 2,172,201 | 1,848,051 | 17.5 | | 母公司擁有人應佔利潤 | 701,396 | 1,113,403 | (37.0) | | 母公司擁有人應佔非國際財務報告 | | | | | 準則經調整淨利潤 | 755,701 | 690,266 | 9.5 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown significant growth in recent months and year-to-date [1] - As of August 21, 2025, the latest net value of the fund is 1.8954 yuan, reflecting a growth of 0.78% [1] - The fund's one-month return is 5.63%, three-month return is 20.86%, and year-to-date return is 25.65%, with respective rankings of 4196 out of 4701, 1241 out of 4632, and 1624 out of 4492 [1] Group 2 - The top ten stock holdings of the fund account for a total of 54.73%, with major positions in WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) [1] - The fund was established on September 29, 2016, and as of June 30, 2025, it has a total scale of 15.163 billion yuan [1] - The fund is managed by two managers: Ge Lan and Zhao Lei, with Ge Lan having a background in biomedical engineering and extensive experience in fund management [2]

Core Viewpoint - The A-share market is experiencing a "slow bull" trend, with major indices reaching new highs and a significant increase in market capitalization and trading volume. However, there are concerns regarding valuation and profit matching, as well as short-term volatility risks [2][3]. Market Analysis - As of August 18, the A-share market has seen 79.79% of stocks with positive returns this year, with 1,152 stocks rising over 50% and 366 stocks doubling in value [3][5]. - The Shanghai Composite Index has surpassed 3,700 points, marking a nearly ten-year high, and the total market capitalization has exceeded 100 trillion yuan [2][3]. Valuation Insights - Despite the overall market rally, the latest price-to-earnings (P/E) and price-to-book (P/B) ratios for major indices like the Shanghai Composite and Shenzhen Composite are at historically low levels, indicating potential value [5][6]. - The Shanghai Composite Index's P/E and P/B ratios are at 15.99 and 1.45, respectively, placing them in the 37.68% and 19.68% historical percentiles, suggesting a relative undervaluation [5][6]. Sector Performance - The North China 50 and CSI 2000 indices have shown significant gains of 51.92% and 31.73% year-to-date, respectively, but are now at historical extremes in terms of valuation [5][6]. - The market is characterized by a "healthy bull" phase, with orderly sector rotation and low volatility, driven by continuous inflow of incremental capital [3][5]. Stock Highlights - A total of 164 companies have reached new historical highs in stock prices, with notable performers including Shangwei New Materials (up 1362.16%) and Guoxin Technology (up 866.40%) [10][11]. - The low-valuation stocks, with P/E and P/B ratios below 30%, are expected to experience value recovery, potentially providing substantial returns for investors [7][8]. Investment Recommendations - Analysts suggest focusing on long-term trends and maintaining diversified portfolios to navigate the current market environment, avoiding the pitfalls of short-term speculation [3][4].

New Stock Activities - Companies currently in the IPO process include Jiaxin International Resources, Shuangdeng Co., and Kanglong Chemical [1] - Other companies in the IPO process are Suteng Juchuang, Jinglian Group, Binjiang Services, and Yika [1] Earnings Announcement Dates - Companies scheduled to announce earnings include Tengsheng Bo Pharmaceutical-B, Chunquan Industrial Trust, and Jinchao Yang Group [1] - Additional companies include Zaitong, China Petroleum & Chemical Corporation, Jinyuan Development International Industry, and Runli Maritime [1] - Other firms set to report earnings are New Fire Technology Holdings, Weijun Group Holdings, and Citic Bank [1] Shareholder Meetings - Companies holding shareholder meetings include Wuxi Life, China Wangwang, Cultural Communication, and Jingneng Clean Energy [1] - Additional companies include GC Construction [1] Dividend Distribution - Companies declaring dividends include Huixian Industrial Trust, Cabin, and Baotan Holdings [1] - Other firms include Pacific Shipping, China New Town, and Victory Securities [1] - Additional companies declaring dividends are Jinsang Machine Tool China, Aihua Credit, and Gaoxin Retail [1] - First Service Holdings is also listed for dividend distribution [1] Dividend Payment Dates - Companies with scheduled dividend payment dates include Midea Real Estate, China Galaxy, CITIC Securities, and China Life [2]

Market Overview - The Hang Seng Index closed at 25,122.90, down 0.21% for the day and up 25.35% year-to-date[3] - The Hang Seng Tech Index decreased by 0.67%, with a year-to-date increase of 23.14%[3] - The Hang Seng China Enterprises Index fell by 3.30% for the day, but is up 23.70% year-to-date[3] Sector Performance - Pharmaceutical outsourcing stocks saw significant declines, with Tigermed down over 8% and other major players like WuXi AppTec and Pharmaron dropping over 5%[9] - Restaurant stocks performed well, with Daoxiang Holdings rising over 11% and other chains like Haidilao increasing by over 2%[9] - Sportswear stocks gained traction, with Anta Sports up over 4% following positive news on the sports industry[9] Investment Trends - Southbound capital recorded a net inflow of HKD 18.573 billion, indicating a stable investment sentiment despite market fluctuations[9] - Electric vehicle manufacturer Leap Motor reported a 174% increase in revenue year-on-year, achieving HKD 24.25 billion in the first half of 2025[9] U.S. Market Insights - U.S. major indices showed mixed results, with concerns over potential hawkish statements from the Federal Reserve influencing investor behavior[9] - Large tech stocks experienced declines, with Nvidia down 3.50% and Meta down 2.07%[9] Global Economic Indicators - Japan's Nikkei 225 index fell by 0.38% as investors took profits after three consecutive days of gains[13] - The U.S. housing starts rose to a five-month high, indicating a potential recovery in the housing market[13]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown varying returns over different time frames and has a significant concentration in its top ten stock holdings [1][3]. Group 2 - The latest net value of the China Europe Medical Health Mixed Fund C is 1.8800 yuan, reflecting a decrease of 1.92%. The fund has a one-month return of 3.52%, ranking 3963 out of 4628 in its category. Over the past six months, it has achieved a return of 25.52%, ranking 653 out of 4465, and a year-to-date return of 24.63%, ranking 1493 out of 4423 [1]. - The fund's top ten stock holdings account for a total of 54.73%, with the largest positions being WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) among others [1]. - As of June 30, 2025, the total scale of the China Europe Medical Health Mixed Fund C is 15.163 billion yuan, managed by fund managers Ge Lan and Zhao Lei [1]. Group 3 - Ge Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014. Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors and joined China Europe Fund Management in 2021 [2].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhaoyan New Drug, which closed at 32.19 yuan with a PE ratio of 62.27 times, indicating a decline of 2.87% [1] - The company operates primarily in the field of non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1] - As of the first quarter of 2025, Zhaoyan New Drug reported a revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.12 million yuan, reflecting a significant increase of 115.11% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical services sector is 49.81 times, with a median of 65.60 times, positioning Zhaoyan New Drug at the 28th rank within the industry [1][2] - The total market capitalization of Zhaoyan New Drug is 24.126 billion yuan, with 17 institutions holding a total of 10.9687 million shares valued at 231 million yuan [1] - The company's sales gross margin stands at 28.61% as per the latest financial report [1]

最新一期业绩显示，2025年一季报，公司实现营业收入3.93亿元，同比16.78%；净利润3831.36万元， 同比14.56%，销售毛利率26.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三博脑科124.01129.755.83136.28亿行业平均 49.8161.684.29199.85亿行业中值65.6068.573.3572.44亿1药明康德19.3528.204.452664.63亿2康龙化成 28.5429.743.80533.28亿3爱尔眼科32.9134.305.591219.76亿4普蕊斯34.0729.172.6331.05亿5诺禾致源 34.2934.432.6467.76亿6华康洁净37.0453.372.0635.66亿7凯莱英37.9539.732.19377.04亿8诺思格 37.9938.812.9254.41亿9通策医疗40.0040.864.87204.90亿10华厦眼科41.0740.472.94173.46亿11万邦医药 45.8436.282.0731.03亿12昭衍新药62.27325.692.98241.26亿 来源：金融界 从行业市盈率 ...